Suchergebnisse - "Schmid, Peter"

PubPharm (633)

61

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

enthalten in: Breast cancer research : BCR | 2021

von Schmid, P. | Sablin, M. | Bergh, J. | +17

62

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

enthalten in: Breast cancer research | 2021

von Schmid, P. | Sablin, M. | Bergh, J. | +17

63

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The lancet / Oncology | May 18, 2021

von Perez-Garcia, J. | Gebhart, G. | Ruiz Borrego, M. | +19

64

Electro-Tactile Feedback to Provide Assistance to Touchscreen Interaction of the Elderly

enthalten in: Advances in human factors and ergonomics in healthcare and medical devices | 2021

von Schmid, P. | Maier, T.

65

Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials

enthalten in: Expert opinion on emerging drugs | 2021

von Hall, P. | Schmid, P.

66

Using adjoint-based optimization to enhance ignition in non-premixed jets

enthalten in: Proceedings. Mathematical, physical, and engineering sciences | 2021

von Qadri, U. | Magri, L. | Ihme, M. | +1

67

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer : A Meta-Analysis

enthalten in: Cancer research | 2020

von Huang, M. | O'Shaughnessy, J. | Zhao, J. | +15

68

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355) : a randomised, placebo-controlled, double-blind, phase 3 clinical trial

enthalten in: Lancet (London, England) | 2020

von Cortes, J. | Cescon, D. | Rugo, H. | +118

CommentIn: Lancet. 2021 Jul 3;398(10294):24. - PMID 34217392

69

Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer : a cross-sectional study evaluating the relationships between disease and treatment stage

enthalten in: Health and quality of life outcomes | 2020

von Verrill, M. | Wardley, A. | Retzler, J. | +6

70

Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage

enthalten in: Health and quality of life outcomes | 2020

von Verrill, M. | Wardley, A. | Retzler, J. | +6